Welcome to our dedicated page for Adlai Nortye Ltd. news (Ticker: $ANL), a resource for investors and traders seeking the latest updates and insights on Adlai Nortye Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adlai Nortye Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adlai Nortye Ltd.'s position in the market.
Adlai Nortye (NASDAQ: ANL) has announced its plans to present preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) at the ASCO 2024 Annual Meeting in Chicago from May 31 to June 4, 2024. AN0025, a selective EP4 inhibitor, has shown antitumor activity by modulating macrophages and immunosuppressive myeloid cells. The study, AN0025S0104, is a single-arm, open-label, multicenter, Phase Ib trial, assessing the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or recurrent esophageal cancer (EC) and esophagogastric junction cancer. Previous studies highlighted the synergistic efficacy of AN0025 with CRT in rectal cancer. Adlai Nortye aims to address unmet patient needs through innovative oncology research.
Adlai Nortye announced the dosing of the first patient in its Phase II clinical trial, named ARTEMIS, for palupiprant (AN0025) in treating locally advanced rectal cancer. This study, led by the Cancer Research UK Clinical Trials Unit at the University of Leeds, aims to compare total neoadjuvant therapy (TNT) with or without AN0025 in patients with moderate to high-risk rectal cancer. The trial involves 140 patients, divided into two groups, and will evaluate clinical complete response (cCR) rate six months post-radiotherapy. The trial builds on encouraging Phase Ib results and seeks to improve efficacy while minimizing invasive surgeries.